FibroBiologics (STU:SG0) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. FibroBiologics's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. FibroBiologics's average Accounts Receivable for the three months ended in Dec. 2024 was €0.00 Mil.

FibroBiologics Receivables Turnover Historical Data

The historical data trend for FibroBiologics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Receivables Turnover Chart

FibroBiologics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

FibroBiologics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Receivables Turnover	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of FibroBiologics's Receivables Turnover

For the Biotechnology subindustry, FibroBiologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FibroBiologics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroBiologics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where FibroBiologics's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

FibroBiologics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

FibroBiologics's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

FibroBiologics's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

FibroBiologics (STU:SG0) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

FibroBiologics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (STU:SG0) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

FBLG:USA

Address

455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598

Website

https://www.fibrobiologics.com

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

FibroBiologics Headlines

No Headlines